Long-acting GLP-1 receptor agonist. Daily injection. Predecessor to semaglutide in the Novo Nordisk GLP-1 lineage.
FDA-approved as Saxenda (obesity) and Victoza (T2D). Demonstrates 5-8% weight reduction at 56 weeks in SCALE trials — superseded by semaglutide and tirzepatide for newer use, but remains a covered option for many insurance formularies.
Daily injection burden vs. weekly semaglutide is real. Same pancreatitis / gallbladder watch. Often used now as bridge while waiting for semaglutide / tirzepatide insurance approval.
C16 palmitoyl group conjugated at K20 via γ-glutamic acid spacer.
Known risk or pharmacological conflict.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Liraglutide (Saxenda for obesity, Victoza for T2D) was the first GLP-1 agonist approved for weight management. SCALE trials showed ~5-8% body-weight reduction at 56 weeks — modest by Tirzepatide / Semaglutide standards but meaningful pre-2017. Daily injection, less convenient than weekly Sema/Tirz. Generic versions filing post-2024 patent expiry.
Liraglutide remains useful when insurance won't cover Wegovy/Zepbound or when patients can't tolerate weekly dosing. With generics arriving, cash-pay cost drops materially. Daily injection is the friction point most users dislike — adherence drops noticeably vs weekly options.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 0.6-3 mg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Saxenda (obesity) and Victoza (T2D). Generics filed; pricing dropping. Daily injection, less convenient than weekly Sema/Tirz.
As of 2026-04Saxenda + Victoza available COFEPRIS-registered MX pharmacies.
As of 2026-04FDA approved (Saxenda / Victoza)
COFEPRIS issued formal warnings about counterfeit Ozempic, Wegovy, and Saxenda circulating in Mexican gray markets, particularly in border-state pharmacies catering to US cross-border traffic. Several seizures documented in Tijuana, Juárez, and Reynosa.
COFEPRIS (Mexican federal health regulator) continued to require physician prescription for GLP-1 agonists through 2023-2024 despite high obesity prevalence and pharmacy-tourism demand from US patients. Compounding less restrictive than US 503A regime.